Article:
Anderson, M.A., Bennett, R. orcid.org/0000-0003-4037-4536, Badoux, X. et al. (22 more authors) (2023) Chronic lymphocytic leukaemia Australasian consensus practice statement. Internal Medicine Journal, 53 (9). pp. 1678-1691. ISSN 1444-0903

https://doi.org/10.1111/imj.16207

INTERNAL MEDICINE JOURNAL

RACP Specialists. Together

Check for updates

doi:10.1111/imj.16207

POSITION PAPER

Chronic lymphocytic leukaemia Australasian consensus practice statement

Mary A. Anderson,[1,2,3] Rory Bennett,[1] Xavier Badoux,[4] Giles Best,[5] Nicole Chia,[6] Tara Cochrane,[7] Gavin Cull,[8] Kyle Crassini,[9] Rosemary Harrup,[10,11] Sharon Jackson,[12] Bryone Kuss,[5] Masa Lasica,[13] Thomas E. Lew,[1,2,3] Paula Marlton,[14] Stephen Opat,[15] Emma Palfreyman,[16] Mark N. Polizzotto,[17,18] Sumita Ratnasingam,[19,20,21] John F. Seymour,[1,22] Asha Soosapilla,[23] Dipti Talaulikar,[24,25,26] Constantine S. Tam,[27] Robert Weinkove,[28,29] Joel Wight[30,31] and Stephen P. Mulligan[32,33]

[1]Department of Clinical Haematology, The Royal Melbourne Hospital and The Peter MacCallum Cancer Centre, [2]Division of Blood Cells and Blood Cancer, The Walter and Eliza Hall Institute, [3]Department of Medical Biology, The University of Melbourne, [13]St Vincent's Hospital, [15]School of Clinical Sciences at Monash Health, Monash University, [22]Department of Medicine, University of Melbourne, and [27]Alfred Hospital and Monash University, Melbourne, [19]St John of God Hospital Geelong, [20]University Hospital Geelong, and [21]School of Medicine, Geelong Clinical School, Deakin University, Geelong, Victoria, [4]St George Hospital, [23]Flow Cytometry, Healius Pathology, and [32]Royal North Shore Hospital, Sydney, [9]Mid North Coast Cancer Institute, Coffs Harbour Health Campus, Coffs Harbour, New South Wales, [5]Flinders University and Medical Centre, Adelaide, South Australia, [6]Genomic Diagnostics, Healius Pathology, and [14]Department of Haematology, Princess Alexandra Hospital and University of Queensland, Brisbane, [7]Gold Coast University Hospital, Griffith University, Gold Coast, [30]Department of Haematology and Bone Marrow Transplantation, Townsville University Hospital, and [31]James Cook University, School of Medicine, Townsville, Queensland, [8]Sir Charles Gairdner Hospital, PathWest Laboratory Medicine and University of Western Australia, Perth, Western Australia, [10]Cancer and Blood Services Royal Hobart Hospital, and [11]Menzies Research Institute, University of Tasmania, Hobart, Tasmania, [16]Royal Darwin Hospital, Darwin, Northern Territory, [17]Department of Clinical Haematology, The Canberra Hospital, [18]Clinical Hub for Interventional Research, The Australian National University, Departments of [24]Diagnostic Genomics, ACT Pathology, and [25]Haematology, ACT Pathology, Canberra Health Services, and [26]Australian National University, Canberra, Australian Capital Territory, Australia, and [12]Te Whatu Ora health New Zealand Counties Manukau, Auckland, and [28]Te Rerenga Ora Blood & Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast & Hutt Valley, and [29]Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand

Key words
CLL, consensus, management, diagnosis.

Correspondence
Mary A. Anderson, 305 Grattan Street, Melbourne, Vic. 3000, Australia.
Email: maryann.anderson2@mh.org.au

Abstract

Chronic lymphocytic leukaemia (CLL) is the most common haematological malignancy in Australia and New Zealand (ANZ). Considerable changes to diagnostic and management algorithms have occurred within the last decade. The availability of next-generation sequencing and measurable residual disease assessment by flow cytometry allow for advanced prognostication and response assessments. Novel therapies, including inhibitors of Bruton's tyrosine kinase (BTKi) and B-cell lymphoma 2 (BCL2) inhibitors, have transformed the treatment landscape for both treatment-naïve and relapsed/

Conflict of Interest: Dr M. A. Anderson is an employee of the Walter and Eliza Hall Institute, which receives milestone payments in relation to venetoclax, in which she is entitled to a share. Dr M. A. Anderson receives honoraria from Abbvie, AstraZeneca, Janssen, Gilead, Novartis, Takeda, MSD and CSL. A/Prof T. Cochrane receives research funding from Beigene. Dr G. Cull has received disclosures for the last 24 months and research funding from Beigene, AstraZeneca and Glycomimetics. Dr R. Harrup serves on the AstraZeneca advisory board. Dr S. Jackson receives honoraria and advisory board participation for Abbvie. Dr P. Marlton: Advisory Board participation and/or speaker fees from Abbvie, Astellas, AstraZeneca, Beigene, Gilead, Janssen, Jazz, MSD, Novartis, Otsuka, Servier, Pfizer and Roche. Prof C. S. Tam receives honoraria from AbbVie, AstraZeneca, Janssen, Beigene and LOXO and research funding from AbbVie, Janssen and Beigene. Dr R. Weinkove receives speaker fees and advisory board participation for Abbvie and Janssen and speaker fees for Beigene. Dr J. Wight receives honoraria, travel funding and advisory boards from Abbvie, Janssen and MSD. Prof S. P. Mulligan receives honoraria or advisory board participation for Abbvie, AstraZeneca, Janssen and Beigene. Dr E. Palfreyman receives honoraria and advisory board participation from Abbvie and AstraZeneca. Dr T. E. Lew is an employee of the Walter and Eliza Hall Institute of Medical Research, which receives milestone and royalty payments related to venetoclax and is a recipient of a share in royalties. Prof J. F. Seymour: AbbVie; honoraria, membership on an entity's board of directors or advisory committees, research funding, speaker's bureau; Janssen; honoraria, membership on an entity's board of directors or advisory committee; TG Therapeutics; consultancy; F. Hoffman-La Roche Ltd.; consultancy, honoraria, membership on an entity's board of directors or advisory committee, research funding, speaker's bureau; Celgene; consultancy, research funding, speaker's bureau; BMS; honoraria, membership on an entity's board of directors or advisory committee; Gilead; honoraria, membership on an entity's board of directors or advisory committee; Genor Biopharma; membership on an entity's board of directors or advisory committee. No conflicts of interest are declared for the remaining authors.

Received 30 November 2022; accepted 30 July 2023.

refractory disease, particularly for patients with high-risk genetic aberrations. Recommendations regarding appropriate supportive management continue to evolve, and special considerations are required for patients with CLL with respect to the global SARS-CoV-2 pandemic. The unique funding and treatment environments in Australasia highlight the need for specific local guidance with respect to the investigation and management of CLL. This consensus practice statement was developed by a broadly representative group of ANZ experts in CLL with endorsement by peak haematology bodies, with a view to providing this standardised guidance.

Introduction

The management and diagnostic paradigms for chronic lymphocytic leukaemia (CLL) have undergone dramatic change over the last decade. This consensus practice statement has been developed by a broadly representative group of Australian and New Zealand (ANZ) experts in CLL with endorsement by peak haematology bodies, with a view to providing standardised guidance to ANZ haematologists and oncologists for the investigation and management of CLL.

Methodology

This consensus practice statement was undertaken by a panel of CLL experts in collaboration with

1. The CLL Working Group of the Australasian Leukaemia and Lymphoma Group
2. Chronic Lymphocytic Leukaemia Australian Research Consortium
3. The Haematology Society of Australia and New Zealand
4. The Australasian Lymphoma Alliance (ALA) and the ALA policy for Consensus Practice Statement development

The authors performed a systematic review of all available literature pertaining to CLL as of April 2023. Relevant literature was selected by the authors following a survey of current literature and international guidelines. The statement was drafted by the authors through an iterative consensus approach[1] during three meetings and subsequent inclusive communication both to the opinions provided and the evidence available. Consensus was reached for all recommendations made with agreed wording per this document. A summary of recommendations is shown after each section with levels of evidence referenced per National Health and Medical Research Council criteria.[2] This practice statement does not necessarily represent the treatment policies of the individual institutions where the authors are employed.

Diagnosis and presentation

Presentation and indications for treatment

CLL is the most common haematological malignancy in ANZ. In Australia, the age-standardised incidence rate is 7.1/100 000 (9.3 for males and 5.1 for females). The median age of diagnosis is 70.9 years, with a risk of diagnosis before age 75 of 0.54% and before age 85 of 0.97%.[3] CLL is a low-grade lymphoproliferative disorder with a peripheral blood lymphocytosis, often identified as an incidental finding on routine blood tests. Most patients are asymptomatic at presentation, and the disease commonly takes an indolent course. A 'watch and wait' strategy is often employed for many years before treatment is required, as there is no survival benefit for early treatment with chemotherapy, chemoimmunotherapy (CIT) or targeted agents.[4–7] The indications for commencement of treatment in the targeted therapy era remain unchanged as per iwCLL[8] criteria.

A significant proportion of patients will never require CLL treatment. The absolute lymphocyte count should not be used as a sole indication for treatment and leukostasis is rare even with markedly elevated lymphocyte counts. Similarly, hypogammaglobulinaemia or recurrent infections are not considered indications to commence CLL-directed therapy, as these disease manifestations are not commonly ameliorated by current CLL-directed therapies. Bone marrow biopsy and CT scanning may be considered appropriate prior to commencement of treatment.

Immunophenotyping

The iwCLL,[8] WHO[9] and NCCN[10] diagnostic criteria for CLL are based on the morphology and immunophenotype of the neoplastic B-cells. CLL cells in peripheral blood (PB) and/or bone marrow (BM) typically co-express CD5, CD19 and CD23 and are light chain restricted with weak/dim expression of surface immunoglobulin (SIg) and CD20. The minimum set of markers required for the diagnosis of CLL is CD19, CD5, CD20, CD23 and light chain clonality.[11]

The WHO 2017[9] and NCCN 2020[10] guidelines for the diagnosis of CLL require ≥5 × 10^9/L circulating monoclonal B-lymphocytes with a typical CLL immunophenotype in the PB.[12] The diagnosis of small lymphocytic lymphoma (SLL) is made if the circulating clone is <5 × 10^9/L with nodal, splenic or other extramedullary involvement and is otherwise identical to CLL. Monoclonal B-Lymphocytosis (MBL) is a circulating B-cell clone <5.0 × 10^9/L in the absence of associated lymphadenopathy, organomegaly or other features of B-cell lymphoproliferative disorder.[13] Most MBLs have a CLL-like immunophenotype.

Genetic testing

Molecular analysis of CLL is generally not required until treatment is indicated. Recommended prognostic tests for CLL are summarised in Table 1. Immunoglobulin heavy chain variable gene (IGHV) mutational status and V-gene usage are important factors for prognosis and prediction of treatment outcome. IGHV mutational status retains its independent prognostic significance except when the patient is treated with Bruton's tyrosine kinase inhibition (BTKi).[18]

Fluorescence *in-situ* hybridisation (FISH) detects focal deletions of chromosomes 13q, 11q and 17p and trisomy 12, which are of prognostic significance.[8,19,20] In the CIT era, del(17p) and del(11q) conferred an unfavourable prognosis[8,21,22] and trisomy 12 an intermediate prognosis.[23] Deletion of 13q as a sole abnormality is associated with a favourable outcome, although deletions encompassing RB1 are often associated with a complex karyotype, altering the prognostic significance.[21,22] Cases may harbour more than one abnormality.

G-band karyotype analysis or single-nucleotide polymorphism or 'chromosomal' microarray provides genome-wide analysis and can detect multiple and complex chromosomal abnormalities. Hence, these may be considered more informative than FISH. The complexity and heterogeneity of chromosomal rearrangements may indicate genomic instability.[21] The presence of mutations affecting *TP53* and/or del(17p) abnormality (collectively referred to as *TP53* aberrancy) remains among the strongest predictors of poor disease response and early relapse.[24] A complex karyotype, defined as ≥5 aberrations,[25] is a marker of adverse prognosis.[26]

Frontline management

Treatment recommendations for CLL requiring therapy are depicted in Figure 1.

The definition of a 'fit' patient with respect to frontline treatment for CLL was initially derived in the era of CIT, most frequently defined as age <65–70 years with a cumulative illness rating scale (CIRS)[27] <6 and a creatinine clearance (CrCl) ≥70 mL/min, while 'unfit' patients are accepted to have advanced age, or CIRS ≥6 and/or CrCl <70 mL/min. These definitions have been used in the design of the major studies comparing novel therapies to CIT.[28–31]

The therapeutic landscape in ANZ is substantially influenced by the Pharmaceutical Benefits Scheme (PBS, Australia) or PHARMAC (NZ), which provides reimbursed

Table 1 Recommended prognostic tests in CLL

Laboratory test	Prior to firstline therapy	Disease response assessment	Prior to subsequent lines of therapy
FISH (17p; 13q; 11q; trisomy 12)	Yes – not required if CMA or standard karyotype performed	No	Yes
Chromosomal (SNP) Microarray (CMA)	Yes, may be used as an alternative to FISH	No	Yes, may be used as an alternative to FISH
Standard karyotype (chromosomal G-banding analysis)	Yes, (i) where CMA is not available, (ii) characterisation of CMA/FISH results	No	No
IGHV mutational status, V-gene use and BCR stereotype	Yes, if not done at diagnosis†·‡	No	No
TP53 mutation	Yes	No	Yes, particularly if evidence of clonal evolution by other molecular testing
MRD analysis	N/A	Yes – usually flow cytometry	N/A
NGS lymphoid panel	Where considered appropriate, although not currently influencing treatment decisions		

†IgHV test not rebated by PBS.

‡IgHV may be performed on peripheral blood satisfying diagnostic criteria for CLL.

BCR, B-cell receptor; CLL, chronic lymphocytic leukaemia; CMA, chromosomal microarray; FISH, fluorescent *in-situ* hybridisation; IGHV, immunoglobulin heavy chain variable; MRD, minimal residual disease; NGS, next-generation sequencing; PBS, Pharmaceutical Benefits Scheme; *TP53*, tumour protein p53; tris 12, trisomy 12.



Figure 1 Frontline treatment of CLL requiring therapy. †High-risk genetic features defined by unmutated IGHV, complex karyotype (≥3), *TP53* dysfunction by del(17p) or *TP53* mutation. ‡Clinical trial. §For IGHV unmutated disease, treatment with FCR is acceptable with acknowledgement of inferior PFS (~4 years) compared to IGHV-mutated (>50% cure rate). CLL, chronic lymphocytic leukaemia; FCR, fludarabine, cyclophosphamide and rituximab; IGHV, immunoglobulin heavy chain variable gene; PFS, progression-free survival.

treatment options. Reimbursed frontline novel therapies in ANZ are currently limited to venetoclax-obinutuzumab (VenO; *Australia only*; patients who are unfit or unsuitable for CIT) and venetoclax monotherapy (*NZ only*; patients with CLL with *TP53* dysfunction). CIT is therefore the only currently funded option for frontline treatment of fit patients in Australia and for patients with non-*TP53* aberrant CLL of any age in New Zealand.

Unfit patients

Chemoimmunotherapy

The CLL 11 trial[32] randomised unfit patients to chlorambucil alone or combined with either rituximab or obinutuzumab and demonstrated chlorambucil-obinutuzumab was superior. For patients >65 years old, no significant difference in median progression-free survival (PFS) was demonstrated following bendamustine-rituximab (BR) compared with fludarabine, cyclophosphamide and rituximab (FCR) and BR was associated with better tolerability of therapy.[33]

BTK inhibitors

Superior PFS and overall survival (OS) were observed with continuous ibrutinib over fixed-duration chlorambucil in unfit patients with CLL without del(17p) in RESONATE 2.[34] The ILLUMINATE[35] and ELEVATE TN[28] studies demonstrated improved PFS with both ibrutinib-obinutuzumab and acalabrutinib (± obinutuzumab) over chlorambucil-obinutuzumab respectively. The ALLIANCE trial[29] (patients ≥ 65 years) demonstrated superior PFS with both ibrutinib monotherapy or ibrutinib-rituximab (PFS identical for I vs I + R) over BR (2-year estimated PFS – 87%, 88% vs 74%, $P < 0.001$) sustained in long-term follow-up.[36] Similarly, in SEQUOIA,[37] zanubrutinib was compared to six cycles of BR in CLL without del(17p), resulting in an estimated 2-year PFS of 85% versus 69% ($P < 0.0001$). Subgroup analysis of several studies (ALLIANCE,[29] ILLUMINATE,[35] ELEVATE TN[28] and SEQUOIA[38]) note the more pronounced PFS advantage of the BTKi arms in patients with adverse CLL biology. A drawback of BTKi therapy is the continuous use schedule until progression or intolerance. Adverse events with BTKi include hypertension and cardiac events (arrhythmias, cardiac failure and sudden death), although these risks are variably lower with second-generation agents. Optimisation of hypertension and cardiac risk factors is important.

The role of BTKi combination therapies has been partially addressed. Adding rituximab to single-agent ibrutinib offers no benefit[29,39]; however, the merits of combining obinutuzumab with other BTKi remain less clear.[28,35] The phase 3 trial GLOW[40] randomised elderly patients with no del(17p) or *TP53* mutation to chlorambucil-obinutuzumab or 12 cycles of venetoclax-ibrutinib preceded by a 3 months lead in with single-agent ibrutinib. Venetoclax-ibrutinib was associated with improved PFS (30 months PFS 80.5% vs 35.8%; $P < 0.0001$); however, increased grade 3/4 adverse events (75.5%; predominantly haematologic) and four sudden cardiac deaths occurred in this arm of the study.

Venetoclax-obinutuzumab

VenO is a generally well-tolerated, time-limited and highly effective regimen in the frontline setting treating elderly unfit patients, as shown in the CLL14 study.[41–43] This study demonstrated that compared to chlorambucil-

obinutuzumab, VenO has higher PFS at 4 years (74% vs 35%) and frequently achieved uMRD remissions (76% in PB 3 months after completion of therapy).[44]

Recommendations. For older/unfit patients BTKi or VenO is superior to CIT, particularly for CLL with high-risk genetic features such as del(17p), unmutated IGHV or complex karyotype (level II). Optimal control of hypertension and cardiac risk factors when using a BTKi and of TLS risk factors when using BCL2i is recommended (level II). If reimbursed access to BCL2i or BTKi is not possible, treatment with chlorambucil-obinutuzumab is reasonable in the absence of high-risk genetic features. Those who have high-risk genetics should be enrolled in a clinical study whenever possible (level II).

Fit patients

Chemoimmunotherapy

The CLL8 trial confirmed that FCR is a highly effective treatment for fit patients with CLL,[45] resulting in high overall response rates (ORR), prolonged PFS, OS and high rates of undetectable minimal residual disease (uMRD) compared to FC without rituximab. Long-term disease control was observed in the majority of IGHV-mutated CLL (PFS at 12.8 years 53.9%; plateaued after 10 years),[46,47] while CLL with unmutated IGHV had an inferior PFS (4.2 years; 12 years PFS 8.9%) with a continuous pattern of relapse. CLL with del(17p) or mutated *TP53* had exceptionally poor outcomes with PFS of ~1 year.[46] Adverse events with CIT include cytopenias, infection and secondary haematological neoplasia (2–3%) with FCR.[46] The CLL10 trial compared BR versus FCR in fit patients with CLL without *TP53* disruption.[33] FCR was associated with a superior PFS in patients less than 65 years of age, but in unplanned *post hoc* analysis, no difference was observed in patients older than 65 years or females.[48]

BTK inhibitors

The NCI-sponsored E1912 trial randomised 529 patients ≤70 years of age (median 57 years) with no del(17p) or *TP53* mutation in a 2:1 ratio to ibrutinib-rituximab (IR) for six cycles, then ibrutinib continuously until disease progression or intolerance, or six cycles of FCR.[30] After a median follow-up of 6 years, IR was superior to FCR for PFS (78% vs 51%; $P < 0.0001$) and OS (95% vs 89%; $P = 0.018$). The PFS for IR was superior to FCR in both IGHV-unmutated CLL (75% vs 33%; $P < 0.0001$) and IGHV-mutated CLL (83% vs 68%; $P = 0.001$). The NCRI FLAIR trial phase I, in a 1:1 randomisation of 771 patients ≤75 years of age (median 62), compared six cycles of FCR with IR with ibrutinib given for up to 6 years. At a median follow-up of 53 months, IR had a superior PFS compared to FCR (median PFS not reached for IR vs 67 months for FCR; $P < 0.001$) but identical OS.[49] In contrast to E1912, PFS was significantly superior with IR for IGHV-unmutated CLL but not significantly different for IGHV-mutated CLL.[51]

BCL2-inhibitor (BCL2i, e.g. venetoclax)

The GAIA/CLL13 trial randomised treatment-naïve fit patients with CLL without *TP53* aberrations to CIT or one of three venetoclax-based combinations. Patients were randomised to six cycles of CIT (FCR ≤ 65 years; BR > 65 years), venetoclax and rituximab (RV), venetoclax and obinutuzumab (GV), or venetoclax, obinutuzumab and ibrutinib (GIV), where ibrutinib could be continued for 36 months in those who did not achieve uMRD.[50,52] At a median follow-up of 38 months, the median PFS was not reached for GIV and GV compared with 52 months for CIT. GIV significantly reduced the relative risk of disease progression by 68% and GV by 58% compared with CIT. The 3-year PFS rates were 90.5% (GIV), 87.7% (GV) and 75.5% (CIT). The median PFS of RV was inferior to GV/GIV combinations yet similar to CIT, suggesting the choice of CD20 antibody is important. Adverse events with BCL2i included tumour lysis syndrome (TLS) and cytopenia; TLS requires dose ramp-up and active prophylaxis according to regimen protocol and published guidelines.

Combination, fixed duration BTKi + BCL2i

The CAPTIVATE FD study examined untreated patients with CLL ≤70 years (median 60 years) with ibrutinib for 3 months, followed by combination of ibrutinib with venetoclax for 12 months. Patients received treatment in either fixed-duration or MRD-guided cohorts. For fixed-duration cohort patients, the ORR was 96%, CR was 55%, and the best uMRD rate in blood was 77% after a median follow-up of 27 months. Investigator-assessed 24-month PFS and OS rates were 95% and 98% respectively. Adverse events of grade 3 or more were most commonly neutropenia in 33% and hypertension in 6%, with one sudden death.[53] Longest follow-up is available for the confirmed MRD patients from the MRD cohort who received subsequent double-blind placebo or ibrutinib, for whom 4-year PFS rates were 88% and 95% respectively.[54]

CLL with del(17p) or TP53 mutation

Outcomes with CIT for this subgroup of patients are very poor.[45] Ibrutinib demonstrates similar PFS for patients with *TP53* aberrant CLL in pooled data from

non-randomised studies[55,56] to that reported in large studies for CLL without *TP53* aberrancy.[30,57] Ibrutinib, acalabrutinib and zanubrutinib demonstrate improved PFS compared with CIT in subgroup analyses of patients with *TP53* aberrant CLL from randomised studies in older, unfit patients.[28,29,35,38] Studies of zanubrutinib in treatment-naïve patients have revealed similar outcomes to CLL without del(17p).[58] Venetoclax is active against *TP53* aberrant disease as continuous monotherapy or fixed-duration therapy in combination with obinutuzumab (VenO).[59,60] While *TP53* aberrancy is associated with inferior PFS among patients receiving VenO in the CLL14, PFS following VenO remained superior compared to ChlO for this patient subgroup.[61]

Recommendations. Novel agent therapy is increasingly preferred over CIT internationally wherever possible[10,62] because of equivalent outcomes among non-high-risk genetic patients and improved safety (level II).

For patients with IGHV unmutated disease, BTKi or venetoclax combination therapies are superior to CIT[30,31,51,52] (level II). For patients with *TP53* dysfunction, BTKi or venetoclax-based therapy should be used wherever possible. Targeted therapy agents (either BTKi or BCL2i-based regimens) should be considered the standard of care for patients with *TP53* dysfunction (level II).

Management of relapsed/refractory CLL

BTKIs and venetoclax consistently give significantly superior results in patients relapsing after prior CIT compared to retreatment with CIT.[63–65]

Venetoclax-based regimens

The phase-III MURANO trial demonstrated significantly superior response rates, PB and BM uMRD, PFS and OS for patients with relapsed/refractory (R/R) CLL following 24 months of fixed-duration venetoclax plus six doses of rituximab (VenR) compared with six cycles of BR. The median PFS with VenR was 54 months, with an estimated 5-year OS rate of 82%. End-of-treatment (EOT) PB uMRD (62%) was associated with significantly prolonged PFS and OS, with 18-month post-treatment PFS of 90%, 64% and 8% among patients with undetectable, low-positive (10^{-4} to 10^{-2}) and high-positive ($>10^{-2}$) EOT MRD respectively.[66]

BTKi therapy

The phase 1b/II PCYC-1102 study confirmed the safety and efficacy of ibrutinib 420 mg daily with ORR 89%, 7-year PFS 34% and 7-year OS 55%, the longest follow-up for any BTKi to date in the R/R setting.[67] The RESONATE study[68] confirmed the superiority of ibrutinib over ofatumumab in all genomic high-risk subgroups, with an improved median PFS (44.1 vs 8.1 months, hazard ratio (HR) 0.148, $P < 0.001$).

The ASCEND study randomised patients to idelalisib or BR (physician choice) or acalabrutinib, a second-generation covalent BTKi.[66] Acalabrutinib demonstrated a significant PFS benefit (median PFS not reached vs 16.8 months; 36-month PFS 63% vs 21%, $P < 0.001$) and maintained in high-risk del(17p) (median PFS not reached vs 13.8 months, 36-month PFS 66% vs 5%).[69] There was no difference in OS rates, likely confounded by the 23% crossover to acalabrutinib. Acalabrutinib has non-inferior PFS to ibrutinib and has been associated with a small but significant reduction in number of cardiovascular adverse events.[70]

Zanubrutinib is another second-generation BTKi, currently only available for CLL in Australasia through clinical trials or compassionate access. The phase III ALPINE study randomised patients to zanubrutinib or ibrutinib. Zanubrutinib demonstrated higher ORR when PR with lymphocytosis was excluded (78.3% vs 62.5%, $P = 0.0006$).[71] After median 29.6 months of follow-up, zanubrutinib was associated with superior PFS compared with ibrutinib (HR 0.65; 95% confidence interval (CI) 0.49–0.86, $P = 0.002$). Superiority was retained in patients with CLL harbouring del(17p) (HR 0.53; 95% CI 0.31–0.88) and other major patient subgroups.[72]

Managing patients with BTKi resistance (commonly mediated by *BTK* C481 mutations) or intolerance remains an area of unmet need, resulting in up to 40% discontinuation rates on long-term follow-up.[73–76] Pirtobrutinib (LOXO-305) is a non-covalent BTKi with a 300-fold higher selectivity for BTK.[77] The phase 1/2 BRUIN study[78] for BTKi pretreated CLL/SLL patients demonstrated ORR 68%, PR 54% with 74% of patients remaining on pirtobrutinib over a median follow-up of 9.4 months.

PI3k inhibitors

Selective inhibitors of the phosphatidylinositol 3-kinase (PI3K) are another treatment option and are PBS-funded in Australia. Idelalisib is inferior to BTKI and venetoclax in R/R CLL.[66,79] PI3Ki are frequently associated with immune-mediated toxicities (e.g. colitis, pneumonitis and hepatitis) and opportunistic infections, therefore usually reserved for patients without other therapeutic options.[80–83] In patients relapsing after BTKIs or

venetoclax-based regimens, the efficacy of PI3K inhibitors is generally poor.[84]

Allogeneic stem cell transplant

The availability of BTKi and BCL2i therapies has diminished the role of allogeneic stem cell transplants. Allogeneic transplant should generally be considered in:

- Younger patients with high-risk prognostic features and a suitable donor, usually after failure of at least one targeted therapy.
- Patients with Richter transformation clonally related to CLL who are in remission after CIT.

Outcomes after transplant do not appear to be adversely impacted by the use of one versus two targeted therapies or prior CIT exposure.[85] The optimal timing of allo-HSCT needs to be individualised and consider various competing risks.

Recommendations

BCL2i and BTKi are preferred in all patients with R/R CLL after prior CIT. The choice between BCL2i and BTKi is largely based on patient-related factors, for example, comorbidities and desire for finite therapy. The choice among BTKi is dependent on toxicity profile and availability. PI3Ki is usually employed after failure of BTKi and BCL2i (level 2).

Sequencing of therapies for R/R CLL

An algorithm for treatment sequencing is depicted in Figure 2.

Patients who have received only CIT are candidates for venetoclax or BTKi. Venetoclax may be preferred for patients with atrial fibrillation, bleeding disorders, uncontrolled hypertension or cardiovascular risk factors or for whom fixed-duration therapy is appealing; BTKi may be preferred in those with a high risk for tumour lysis syndrome.

Data available suggest that effective bidirectional salvageability is possible after prior treatment with either BTKi or BCL2i.[84,86] Emerging data suggest that venetoclax retreatment can be effective for relapse after time-limited therapy; however, this is not currently funded outside of clinical trials.[87–89] PI3K inhibitors are an option for R/R CLL, which has failed both BTKi and venetoclax.[90] Clinical trials are strongly recommended in this context.



Figure 2 Sequencing of therapy in second and subsequent relapse of CLL. Note that frontline BTKi is not PBS funded at the time of publication. †Repeat CIT may be considered if relapse occurs after >3 years, if venetoclax and BTKi are contraindicated or not tolerated. ‡Alternative BTKi can be tried in event of intolerance, but are unlikely to be beneficial following covalent BTKi failure. BTKi, Bruton's tyrosine kinase inhibitor; CIT, chemoimmunotherapy; CLL, chronic lymphocytic leukaemia; PBS, Pharmaceutical Benefits Scheme.

Supportive care

Infection is the leading cause of death in people with CLL.[91] Predisposition to infection in CLL is multifactorial, encompassing B-cell dysfunction (including hypogammaglobulinaemia), T-cell dysfunction, defects of complement function and impaired phagocytic function. CLL therapies add further to infection risk, exacerbating dysfunction of both adaptive and innate immunity.[92]

Vaccination

Although humoral responses to vaccination are impaired in people with CLL, vaccination against certain pathogens is strongly recommended (see Table 2), ideally prior to CLL therapy. Most vaccines are safe, but live attenuated vaccines, such as Zostavax, the yellow fever vaccine, BCG and MMR, are contraindicated. Shingrix is safe and effective for shingles prevention in CLL but is not currently PBS-funded. If a patient has received anti-CD20 mAb therapy, some vaccines may be better deferred until 6–12 months after the last anti-CD20 mAb dose to optimise humoral responses. Deferral of SARS-CoV-2 vaccination is not recommended as patients usually develop T-cell responses to mRNA SARS-CoV-2 vaccines[93] and the risks of COVID-19 are high in CLL. Multiple SARS-CoV-2 vaccine doses improve rates of seroconversion, provide higher anti-spike antibody levels and improve SARS-CoV-2-specific T-cell responses.[94]

Pretreatment testing

Hepatitis B serology (HBsAg and HBcAb) must be checked before commencing CLL or other immunosuppressive therapy because of the risk of life-threatening hepatitis B reactivation. Patients who are HBcAb positive but HBsAg negative may require prophylactic antiviral therapy and hepatitis B viral load monitoring throughout treatment until at least 24 months after B-cell suppression. Hepatitis C status should be checked before immunosuppressive therapy and eradication may be recommended prior to treatment if therapy can be safely deferred.

Antimicrobial prophylaxis

Prophylactic antimicrobial treatments can be utilised in selected patients during CLL therapies. Possible regimens are summarised in Supporting Information, Table S1.

Immunoglobulin replacement

Acquired hypogammaglobulinaemia is common in CLL, with incidence rising following CLL therapy.[95] Immunoglobulin (Ig) replacement therapy (IgRT) reduces the incidence of bacterial infections, although its effect on mortality remains unproven.[96] IgRT is approved, widely used in Australia, and should be considered in patients with either IgG level < 4 g/L, or between 4 g/L and lower limit of reference range with a history of either one life-threatening bacterial infection within 12 months or two or more serious bacterial infections within 5 months requiring hospitalisation or intravenous antibiotics.[97] IgRT may be administered by either 4-weekly intravenous or weekly subcutaneous regimen.[98,99] Acquired hypogammaglobulinaemia often persists long term, but a trial of IgRT cessation should be considered.[99]

SARS-CoV-2

People with CLL are at increased risk of dismal outcome with severe COVID-19 and should be vaccinated against SARS-CoV-2, although the serological response to vaccination is substantially impaired.[16,93,100] People with CLL who develop COVID-19 may be eligible for COVID-19-specific therapies. Primary prophylaxis against COVID-19 with long-acting monoclonal antibodies (e.g. tixagevimab/cilgavimab, Evusheld) has been useful but at the time of final submission has largely lost activity against current Omicron-strains.

Table 2 Recommended vaccines for people with CLL

Pathogen	Timing	Suggested vaccine schedule	Reference(s)
Streptococcus pneumoniae	At diagnosis	PCV13 (conjugate, Prevenar); 23PPV (polysaccharide, Pneumovax) 8 weeks later; 23PPV booster after 5 years	Svensson *et al.*[14] Schuh *et al.*[15]
SARS-CoV-2	At diagnosis	mRNA vaccine: 3 primary doses followed by booster dose(s)†	McCaughan *et al.*[16]
Influenza	At diagnosis	Annual vaccination	Schuh *et al.*[15]
Varicella zoster	At diagnosis	VZV recombinant vaccine (Shingrix), two doses 8–16 weeks apart (Live attenuated vaccine such as Zostervax is contra-indicated).	Dagnew *et al.*[17]

†These recommendations may change.
CLL, chronic lymphocytic leukaemia.

Early antiviral treatment is recommended if COVID-19 infection occurs. Potential for drug interactions between antiviral therapy and targeted agents for CLL should be considered – the ritonavir component of Paxlovid is a strong CYP3A4 inhibitor and may require short-term dose modification or interruption of venetoclax and BTK inhibitors while on antiviral therapy.

Secondary malignancy in CLL

The higher risk of secondary primary malignancy (SPM) associated with CLL has been recognised for many years.[101–106] There is a significantly increased risk of SPM and skin cancer (SC) in CLL.[107] There are CLL-specific recommendations for routine skin cancer surveillance, given the high risk in this group.[108] Patients with CLL should follow standard guidelines for other cancer screening.

Response assessments

Response assessment in CLL follows iwCLL guidelines.[8] Achieving uMRD is the strongest prognostic marker of response except with BTKi therapy.[31,109,110] Whether patients who are MRD positive at the end of treatment benefit from treatment intensification, consolidation and maintenance strategies remains a research question. The European Research Initiative on CLL (ERIC) proposed a standardised approach to the detection of MRD by flow cytometry in CLL. The presence of MRD is reported as the percentage of CLL cells within the total leukocyte population. Conventionally, uMRD is defined by threshold of <0.01% or $< 10^{-4}$ (i.e. <1 CLL cell per 10 000 leukocytes).[111,112] MRD can also be measured by quantitative PCR or massively parallel sequencing,[113] which has shown good concordance with flow cytometry results at the 0.010% (10^{-4}) level.

Recommendations

- Response should be assessed by iwCLL criteria[8] using full blood examination; clinical assessment of the lymph nodes, liver and spleen; including imaging by contrast-enhanced CT of the neck, chest, abdomen and pelvis where clinically indicated.
- Bone marrow examination is recommended for response assessment in cases where there are unexplained persistent cytopenias, where documentation of CR is desirable, or where MRD is negative in the peripheral blood, and increased sensitivity is desired.
- MRD testing may be performed for prognostication for patients on finite therapy but is not required in all circumstances.
- There is no evidence supporting routine surveillance imaging and bone marrow assessments for monitoring relapse or progression; clinical and blood assessments are usually adequate.

Special circumstances

The incidence of CLL is not specifically described in rural/regional Australia or in the Indigenous population, though the incidence of all forms of leukaemia appears not significantly different.[114] The NZ Cancer Registry suggests that Māori are at similar risk of lymphoid leukaemia as non-Māori, although age-adjusted incidence has not been reported.[115]

Conclusion

The management of CLL has been revolutionised over the last decade. There is an improved understanding of CLL biology, and equitable access to molecular testing is desired to guide therapy. Three new classes of therapeutics have become available, and this has translated into better outcomes for patients. Further studies on optimal combinations and time-limited therapies remain the focus for future research.

Acknowledgements

A special thanks to learned colleagues who provided invaluable feedback on this consensus statement but could not be listed as authors, including Professor Andrew Roberts (Blood Cells and Blood Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia), Professor Andrew Grigg (Department Clinical Haematology, Austin Hospital, Heidelberg, Melbourne, Australia), Professor Judith Trotman (Haematology Department, University of Sydney, Concord, NSW, Australia), Associate Professor Eliza Hawkes (Olivia Newton-John Cancer Research Institute at Austin Health, Melbourne, Victoria, Australia), Professor Chan Cheah (Department of Haematology, Sir Charles Gairdner Hospital, Perth, WA, Australia) and Dr Kah Lok Chan (Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia). This consensus statement has been endorsed by (i) the Scientific Advisory Committee of the Australian Leukaemia and Lymphoma Group, (ii) the Australian Lymphoma Alliance and (iii) the Haematology Society of Australia and New Zealand. Open access publishing facilitated by The University of Melbourne, as part of the Wiley - The University of Melbourne agreement via the Council of Australian University Librarians.

References

1 Chater AM, Shorter GW, Swanson V, Kamal A, Epton T, Arden MA *et al*. Template for Rapid Iterative Consensus of Experts (TRICE). *Int J Environ Res Public Health* 2021; **18**: 10255.

2 National Health and Medical Research Council. NHMRC Levels of Evidence and Grades for Recommendations for Guideline Developers. [Internet]. National Health and Medical Research Council; 2009. Available from URL: https://www.nhmrc.gov.au/_files_nhmrc/file/guidelines/developers/nhmrc_levels_grades_evidence_120423.pdf

3 Australian Institute of Health and Welfare (AIHW). *Australian Cancer Incidence and Mortality (ACIM) Books: Chronic Lymphocytic Leukaemia [Internet]*. Canberra: AIHW; 2021. Available from URL: http://www.aihw.gov.au/acim-books

4 Catovsky D, Richards S, Fooks J, Hamblin TJ. CLL trials in the United Kingdom the Medical Research Council CLL trials 1, 2 and 3. *Leuk Lymphoma* 1991; **5**: 105–11.

5 Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R *et al*. Chlorambucil in indolent chronic lymphocytic leukemia. *N Engl J Med* 1998; **338**: 1506–14.

6 Herling CD, Cymbalista F, Groß-Ophoff-Müller C, Bahlo J, Robrecht S, Langerbeins P *et al*. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. *Leukemia* 2020; **34**: 2038–50.

7 Langerbeins P, Zhang C, Robrecht S, Cramer P, Fürstenau M, Al-Sawaf O *et al*. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. *Blood* 2022; **139**: 177–87.

8 Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H *et al*. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. *Blood* 2018; **131**: 2745–60.

9 Swerdlow SH, Campo E, Harris NL, Jaffe ES. World health organization classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edn. IARC, Lyon; 2017.

10 Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D *et al*. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 4. 2020, NCCN clinical practice guidelines in oncology. *J Natl Compr Cancer Netw* 2020; **18**: 185–217.

11 Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P *et al*. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. *Cytometry B Clin Cytom* 2018; **94**: 121–8.

12 Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E *et al*. The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: lymphoid neoplasms. *Leukemia* 2022; **36**: 1720–48.

13 Tang C, Shen Y, Soosapilla A, Mulligan SP. Monoclonal B-cell lymphocytosis – a review of diagnostic criteria, biology, natural history, and clinical management. *Leuk Lymphoma* 2022; **29**: 1–12.

14 Svensson T, Kättström M, Hammarlund Y, Roth D, Andersson PO, Svensson M *et al*. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group. *Vaccine* 2018; **36**: 3701–7.

15 Schuh AH, Parry-Jones N, Appleby N, Bloor A, Dearden CE, Fegan C *et al*. Guideline for the treatment of chronic lymphocytic leukaemia. *Br J Haematol* 2018; **182**: 344–59.

16 McCaughan G, Di Ciaccio P, Ananda-Rajah M, Gilroy N, MacIntyre R, Teh B *et al*. COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. *Intern Med J* 2021; **51**: 763–8.

17 Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S *et al*. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. *Lancet Infect Dis* 2019; **19**: 988–1000.

18 Crombie J, Davids MS. IGHV mutational status testing in chronic lymphocytic leukemia. *Am J Hematol* 2017; **92**: 1393–7.

19 Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L *et al*. Genomic aberrations and survival in chronic lymphocytic leukemia. *N Engl J Med* 2000; **343**: 1910–6.

20 Gunn SR, Mohammed MS, Gorre ME, Cotter PD, Kim J, Bahler DW *et al*. Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. *J Mol Diagn* 2008; **10**: 442–51.

21 Chun K, Wenger GD, Chaubey A, Dash DP, Kanagal-Shamanna R, Kantarci S *et al*. Assessing copy number aberrations and copy-neutral loss-of-heterozygosity across the genome as best practice: an evidence-based review from the Cancer Genomics Consortium (CGC) working group for chronic lymphocytic leukemia. *Cancer Genet* 2018; **228–229**: 236–50.

22 Zalcberg I, D'Andrea MG, Monteiro L, Pimenta G, Xisto B. Multidisciplinary diagnostics of chronic lymphocytic leukemia: European Research Initiative on CLL – ERIC recommendations. *Hematol Transfus Cell Ther* 2020; **42**: 269–74.

23 Abruzzo LV, Herling CD, Calin GA, Oakes C, Barron LL, Banks HE *et al*. Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways. *Haematologica* 2018; **103**: 2069–78.

24 Campo E, Cymbalista F, Ghia P, Jäger U, Pospisilova S, Rosenquist R *et al*. TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. *Haematologica* 2018; **103**: 1956–68.

25 Leeksma AC, Baliakas P, Moysiadis T, Puiggros A, Plevova K, van der Kevie-Kersemaekers AM *et al*. Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. *Haematologica* 2020; **106**: 87–97.

26 Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F *et al*. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. *Blood* 2019; **133**: 1205–16.

27 Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the cumulative illness rating scale in a geriatric residential population. *J Am Geriatr Soc* 1995; **43**: 130–7.

28 Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW *et al*. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. *Lancet* 2020; **395**: 1278–91.

29 Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W *et al*. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. *N Engl J Med* 2018; **379**: 2517–28.

30 Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O'Brien S, Barrientos J *et al*. Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. *Blood* 2022; **140**: 112–20.

31 Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M *et al*. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. *N Engl J Med* 2019; **380**: 2225–36.

32 Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM *et al*. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. *N Engl J Med* 2014; **370**: 1101–10.

33 Eichhorst B, Fink A-M, Bahlo J, Busch R, Kovacs G, Maurer C *et al*. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. *Lancet Oncol* 2016; **4846**: 845–942.

34 Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P *et al*. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. *N Engl J Med* 2015; **373**: 2425–37.

35 Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L *et al*. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol* 2019; **20**: 43–56.

36 Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W *et al*. Long-term results of alliance A041202 show continued advantage of Ibrutinib-based regimens compared with Bendamustine plus Rituximab (BR) chemoimmunotherapy. *Blood* 2021; **138**: 639.

37 Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W *et al*. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. *Lancet Oncol* 2022; **23**: 1031–43.

38 Tam CS, Giannopoulos K, Jurczak W, Šimkovič M, Shadman M, Österborg A *et al*. SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). *Blood* 2021; **138**: 396.

39 Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z *et al*. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. *Blood* 2019; **133**: 1011–9.

40 Kater AP, Carolyn O, Carol M, George F, Talha M, Mark-David L *et al*. Fixed-duration Ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. *NEJM Evid* 2022; **1**: EVIDoa2200006.

41 Mauro FR, Reda G, Arena V, Trentin L, Coscia M, Sportoletti P *et al*. Efficacy and safety of front-line venetoclax and rituximab (VenR) for the treatment of Young patients with chronic lymphocytic leukemia and an unfavorable biologic profile. Preliminary results of the Gimema study 'Veritas'. *Blood* 2020; **136**: 47–9.

42 Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G *et al*. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. *Blood* 2018; **132**: 2446–55.

43 Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S *et al*. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. *Blood* 2017; **129**: 2702–5.

44 Al-Sawaf O, Zhang C, Lu T, Liao MZ, Panchal A, Robrecht S *et al*. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. *J Clin Oncol* 2021; **39**: 4049–60.

45 Hallek M, Fischer K, Fingerle-Rowson G, Fink A, Busch R, Mayer J *et al*. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. *Lancet* 2010; **376**: 1164–74.

46 Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P *et al*. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. *Blood* 2016; **127**: 208–15.

47 Thompson PA, Tam CS, O'Brien SM, Wierda WG, Stingo F, Plunkett W *et al*. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. *Blood* 2016; **127**: 303–9.

48 Kutsch N, Bahlo J, Robrecht S, Franklin J, Zhang C, Maurer C *et al*. Long term follow-up data and health-related quality of life in frontline therapy of fit patients treated with FCR versus BR (CLL10 trial of the GCLLSG). *HemaSphere* 2020; **4**: e336.

49 Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B *et al*. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 2023; **24**: 535–52.

50 Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C *et al*. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. *N Engl J Med* 2023; **388**: 1739–54.

51 Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B *et al*.

Ibrutinib plus rituximab is superior to FCR in previously untreated CLL: results of the phase III NCRI FLAIR trial. *Blood* 2021; **138**: 642.
52 Eichhorst B, Niemann C, Kater A. Time-limited venetoclax-obinutuzumab +/- ibrutinib is superior chemoimmunotherapy in frontline chronic lymphocytic leukaemia (CLL): PFS co-primary endpoint of the randomised phase 3 GAIA/CLL13 trial. 2022 EHA Congress; 2022 Jun 9; Vienna, Austria.
53 Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S *et al*. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. *Blood* 2022; **139**: 3278–89.
54 Allan JN, Siddiqi T, Kipps TJ, Kuss BJ, Badoux XC, Barrientos JC *et al*. Treatment outcomes after undetectable MRD with first-line Ibrutinib (Ibr) plus venetoclax (Ven): fixed duration treatment (placebo) versus continued Ibr with up to 5 years median follow-up in the CAPTIVATE study. *Blood* 2022; **140**: 224–7.
55 Allan JN, Shanafelt T, Wiestner A, Moreno C, O'Brien SM, Braggio E *et al*. Long-term efficacy of first-line Ibrutinib treatment for chronic lymphocytic leukemia (CLL) with 4 years of follow-up in patients with TP53 aberrations (del(17p) or TP53 mutation): a pooled analysis from 4 clinical trials. *Blood* 2020; **136**: 23–4.
56 Ahn IE, Tian X, Wiestner A. Ibrutinib for chronic lymphocytic leukemia with TP53 alterations. *N Engl J Med* 2020; **383**: 498–500.
57 Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L *et al*. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab *versus* chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. *Haematologica* 2022; **107**: 2108–20.
58 Tam CS, Robak T, Ghia P, Kahl BS, Walker P, Janowski W *et al*. Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion. *Haematologica* 2020; **106**: 2354–63.
59 Anderson MA, Tam C, Lew TE, Juneja S, Juneja M, Westerman D *et al*. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. *Blood* 2017; **129**: 3362–70.
60 Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S *et al*. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. *J Clin Oncol* 2018; **36**: 1973–80.
61 Tausch E, Schneider C, Robrecht S, Zhang C, Dolnik A, Bloehdorn J *et al*. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. *Blood* 2020; **135**: 2402–12.
62 Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP *et al*. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2021; **32**: 23–33.
63 Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S *et al*. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. *Lancet Oncol* 2016; **17**: 200–11.
64 Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S *et al*. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. *N Engl J Med* 2018; **378**: 1107–20.
65 Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M *et al*. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2017; **18**: 297–311.
66 Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M *et al*. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. *J Clin Oncol* 2020; **38**: 2849–61.
67 Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K *et al*. Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib/II PCYC-1102 study. *Clin Cancer Res Off J Am Assoc Cancer Res* 2020; **26**: 3918–27.
68 Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM *et al*. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. *Am J Hematol* 2019; **94**: 1353–63.
69 Jurczak W, Pluta A, Wach M, Lysak D, Kozak T, Šimkovič M *et al*. Three-year follow-up of the ascend trial: acalabrutinib vs rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia. *Blood* 2021; **138**: 393.
70 Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR *et al*. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. *J Clin Oncol* 2021; **39**: 3441–52.
71 Hillmen P, Eichhorst B, Brown JR, Lamanna N, 'Brien SM, Tam CS *et al*. Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III J Clin Oncol 2023; 41: 1035–45.
72 Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N *et al*. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. *N Engl J Med* 2023; **388**: 319–32.
73 Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S *et al*. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. *Blood Adv* 2019; **3**: 1799–807.
74 Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA *et al*. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. *N Engl J Med* 2013; **369**: 32–42.
75 Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P *et al*.

Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. *Cancer Discov* 2014; **4**: 1022–35.
76 Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A *et al*. BTKC481S-mediated resistance to Ibrutinib in chronic lymphocytic leukemia. *J Clin Oncol* 2017; **35**: 1437–43.
77 Brandhuber B, Gomez E, Smith S, Eary T, Spencer S, Rothenberg SM *et al*. LOXO-305, a next generation reversible BTK inhibitor, for overcoming acquired resistance to irreversible BTK inhibitors. *Clin Lymphoma Myeloma Leuk* 2018; **18**: S216.
78 Mato AR, Pagel JM, Coombs CC, Shah NN, Lamanna N, Munir T *et al*. Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: updated results from the phase 1/2 BRUIN study. *Blood* 2021; **138**: 391.
79 Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM *et al*. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. *Ann Oncol* 2017; **28**: 1050–6.
80 Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P *et al*. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *N Engl J Med* 2014; **370**: 997–1007.
81 Lunning M, Vose J, Nastoupil L, Fowler N, Burger JA, Wierda WG *et al*. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. *Blood* 2019; **134**: 1811–20.
82 Davids MS, Kuss BJ, Hillmen P, Montillo M, Moreno C, Essell J *et al*. Efficacy and safety of duvelisib following disease progression on ofatumumab in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study. *Clin Cancer Res* 2020; **26**: 2096–103.
83 Davids MS, Kim HT, Nicotra A, Savell A, Francoeur K, Hellman JM *et al*. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. *Lancet Haematol* 2019; **6**: e38–47.
84 Mato AR, Roeker LE, Jacobs R, Hill BT, Lamanna N, Brander D *et al*. Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy. *Clin Cancer Res* 2020; **26**: 3589–96.
85 Roeker LE, Dreger P, Brown JR, Lahoud OB, Eyre TA, Brander DM *et al*. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. *Blood Adv* 2020; **4**: 3977–89.
86 Lin VS, Lew TE, Handunnetti SM, Blombery P, Nguyen T, Westerman DA *et al*. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. *Blood* 2020; **135**: 2266–70.
87 Lew TE, Tam CS, Seymour JF. How I treat chronic lymphocytic leukemia after venetoclax. *Blood* 2021; **138**: 361–9.
88 Thompson MC, Mato AR. Treatment of relapsed chronic lymphocytic leukemia after venetoclax. *Hematol Am Soc Hematol Educ Program* 2020; **2020**: 18–23.
89 Seymour JF, Kipps TJ, Eichhorst BF, D'Rozario J, Owen CJ, Assouline S *et al*. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. *Blood* 2022; **140**: 839–50.
90 Lew TE, Lin VS, Cliff ER, Blombery P, Thompson ER, Handunnetti SM *et al*. Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. *Blood Adv* 2021; **5**: 4054–8.
91 Rotbain EC, Niemann CU, Rostgaard K, da Cunha-Bang C, Hjalgrim H, Frederiksen H. Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death. *Leukemia* 2021; **35**: 2570–80.
92 Tadmor T, Welslau M, Hus I. A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia. *Expert Rev Hematol* 2018; **11**: 57–70.
93 Shen Y, Freeman JA, Holland J, Solterbeck A, Naidu K, Soosapilla A *et al*. COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity. *Br J Haematol* 2022; **197**: 41–51.
94 Shen Y, Freeman JA, Holland J, Naidu K, Solterbeck A, Van Bilsen N *et al*. Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion. *Blood* 2022; **140**: 2709–21.
95 Parikh SA, Leis JF, Chaffee KG, Call TG, Hanson CA, Ding W *et al*. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes. *Cancer* 2015; **121**: 2883–91.
96 Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. *Leuk Lymphoma* 2009; **50**: 764–72.
97 National Blood Authority. *Criteria for the Clinical Use of Intravenous Immunoglobulin in Australia*, Second edn. Canberra: National Blood Authority; 2012.
98 Chai KL, Wong JWK, Weinkove R, Keegan A, Crispin PJ, Stanworth SJ *et al*. Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis. *Blood Adv* 2023; **7**: 20–31.
99 Keegan A, Dennington PM, Dhondy N, Mulligan SP. Immunoglobulin replacement therapy in chronic lymphocytic leukaemia patients with hypogammaglobulinaemia and infection. *Eur J Haematol* 2022; **108**: 460–8.
100 Langerbeins P, Eichhorst B. Immune dysfunction in patients with chronic lymphocytic leukemia and challenges during COVID-19 pandemic. *Acta Haematol* 2021; **144**: 508–18.
101 Manusow D, Weinerman BH. Subsequent neoplasia in chronic lymphocytic leukemia. *JAMA* 1975; **232**: 267–9.
102 Tsimberidou AM, Wen S, McLaughlin P, O'Brien S, Wierda WG, Lerner S *et al*. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. *J Clin Oncol* 2009; **27**: 904–10.

103 Benjamini O, Jain P, Trinh L, Qiao W, Strom SS, Lerner S *et al*. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. *Leuk Lymphoma* 2015; **56**: 1643–50.
104 Ishdorj G, Beiggi S, Nugent Z, Streu E, Banerji V, Dhaliwal D *et al*. Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival. *Leuk Lymphoma* 2019; **60**: 3204–13.
105 Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE *et al*. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. *Blood* 1998; **92**: 1165–71.
106 da Cunha-Bang C, Rostgaard K, Andersen MA, Rotbain EC, Grønbæk K, Frederiksen H *et al*. Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study. *Br J Haematol* 2021; **193**: 339–45.
107 Shen Y, Coyle L, Kerridge I, Stevenson W, Arthur C, McKinlay N *et al*. Second primary malignancies in chronic lymphocytic leukaemia: skin, solid organ, haematological and Richter's syndrome. *eJHaem* 2022; **3**: 129–38.
108 Mulcahy A, Mulligan SP, Shumack SP. Recommendations for skin cancer monitoring for patients with chronic lymphocytic leukemia. *Leuk Lymphoma* 2018; **59**: 578–82.
109 Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J *et al*. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL study group. *J Clin Oncol* 2016; **34**: 3758–65.
110 Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G *et al*. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. *J Clin Oncol* 2012; **30**: 980–8.
111 Rawstron AC, Kennedy B, Evans PAS, Davies FE, Richards SJ, Haynes AP *et al*. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. *Blood* 2001; **98**: 29–35.
112 Wierda WG, Rawstron A, Cymbalista F, Badoux X, Rossi D, Brown JR *et al*. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. *Leukemia* 2021; **35**: 3059–72.
113 Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J *et al*. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. *Leukemia* 2016; **30**: 929–36.
114 AIHW. Indigenous Life Expectancy and Deaths [Internet]. Available from URL: https://www.aihw.gov.au/reports/australias-health/indigenous-life-expectancy-and-deaths
115 Ministry of Health. *Cancer: New Registrations and Deaths 2013*. Wellington: Ministry of Health; 2016.

Supporting Information

Additional supporting information may be found in the online version of this article at the publisher's web-site:

Table S1. Recommended antimicrobial prophylaxis.